BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
76.03
-2.15 (-2.75%)
At close: Nov 20, 2026, 4:00 PM EST
78.65
+2.62 (3.45%)
After-hours: Nov 20, 2026, 7:31 PM EST
BridgeBio Pharma Employees
As of September 30, 2026, BridgeBio Pharma had 1,085 total employees, including 1,081 full-time and 4 part-time employees. The number of employees increased by 246 or 29.32% compared to the same quarter last year. That makes BridgeBio Pharma the 14,290th largest employer in the world and 2,116th in the United States.
Employees
1,085
Change (1Y)
246
Growth (1Y)
29.32%
Revenue / Employee
$871,465
Profits / Employee
-$545,737
Market Cap
14.81B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2026 | 1,085 | 246 | 29.32% | 1,081 | 4 |
| Jun 30, 2026 | 1,003 | - | - | 999 | 4 |
| Dec 31, 2025 | 839 | 109 | 14.93% | 834 | 5 |
| Dec 31, 2024 | 730 | 174 | 31.29% | 725 | 5 |
| Dec 31, 2023 | 556 | 160 | 40.40% | 550 | 6 |
| Dec 31, 2022 | 396 | -182 | -31.49% | 392 | 4 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
BBIO News
- 4 days ago - Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM - GlobeNewsWire
- 5 days ago - BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference - Transcripts
- 8 days ago - BridgeBio Pharma price target raised to $91 from $88 at Morgan Stanley - TheFly
- 10 days ago - BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026 - GlobeNewsWire
- 12 days ago - BridgeBio to Participate in November and December Investor Conferences - GlobeNewsWire
- 14 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 - GlobeNewsWire
- 19 days ago - BridgeBio Pharma price target raised to $108 from $106 at Canaccord - TheFly